IN2014DN07109A - - Google Patents

Info

Publication number
IN2014DN07109A
IN2014DN07109A IN7109DEN2014A IN2014DN07109A IN 2014DN07109 A IN2014DN07109 A IN 2014DN07109A IN 7109DEN2014 A IN7109DEN2014 A IN 7109DEN2014A IN 2014DN07109 A IN2014DN07109 A IN 2014DN07109A
Authority
IN
India
Prior art keywords
vgf
relates
qc1qr
tlqp
peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Kenji Okuse
Alessandro Pristera
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN07109(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of IN2014DN07109A publication Critical patent/IN2014DN07109A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN7109DEN2014 2012-01-26 2013-01-25 IN2014DN07109A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1201332.2A GB201201332D0 (en) 2012-01-26 2012-01-26 Method
PCT/GB2013/050162 WO2013110945A1 (fr) 2012-01-26 2013-01-25 Méthodes de traitement de la douleur par le biais de l'inhibition de l'activité du vgf

Publications (1)

Publication Number Publication Date
IN2014DN07109A true IN2014DN07109A (fr) 2015-04-24

Family

ID=45876134

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7109DEN2014 IN2014DN07109A (fr) 2012-01-26 2013-01-25

Country Status (5)

Country Link
US (1) US9718879B2 (fr)
EP (1) EP2807191B8 (fr)
GB (1) GB201201332D0 (fr)
IN (1) IN2014DN07109A (fr)
WO (1) WO2013110945A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180100153A1 (en) * 2016-10-07 2018-04-12 Truebio LLC Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in VGF expressing cancers

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (fr) 1990-08-02 1992-02-20 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
PT1196188E (pt) * 1999-07-21 2005-10-31 Amgen Inc Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv
US20070015145A1 (en) * 2001-08-14 2007-01-18 Clifford Woolf Nucleic acid and amino acid sequences involved in pain
ES2335276T3 (es) 2002-03-13 2010-03-24 Array Biopharma, Inc. Derivados de bencimidazol alquilado n3 como inhibidores de mek.
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (fr) 2003-07-01 2005-01-13 Celltech R & D Limited Fragments d'anticorps fab modifies
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
CN101626767A (zh) 2005-05-18 2010-01-13 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
JP2009543806A (ja) 2006-07-13 2009-12-10 バーナム インスティテュート フォー メディカル リサーチ ｇＣ１ｑＲ／ｐ３２を標的化するための方法および組成物
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
WO2010111702A1 (fr) 2009-03-27 2010-09-30 The Research Foundation Of State University Of New York Méthodes pour prévenir et traiter l'angio-oedème
EA201101533A1 (ru) 2009-04-21 2012-05-30 Новартис Аг Гетероциклические соединения в качестве ингибиторов mek
KR101865426B1 (ko) 2010-06-09 2018-07-13 다나-파버 캔서 인스티튜트 인크. Raf와 mek 억제제에 대한 내성을 부여하는 mek1 돌연변이

Also Published As

Publication number Publication date
EP2807191B8 (fr) 2019-10-16
WO2013110945A1 (fr) 2013-08-01
GB201201332D0 (en) 2012-03-14
US20140370024A1 (en) 2014-12-18
EP2807191A1 (fr) 2014-12-03
US9718879B2 (en) 2017-08-01
EP2807191B1 (fr) 2019-07-10

Similar Documents

Publication Publication Date Title
WO2013188813A3 (fr) Nouveaux agents thérapeutiques pour le cancer du cerveau
ZA202208792B (en) Methods of treating and preventing graft versus host disease
WO2015031564A3 (fr) Composés de la série des 1h-benzo[d]imidazoles substitués à titre d'inhibiteurs de déméthylase 1 spécifique de la lysine (lsd1)
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
IN2015DN01197A (fr)
IN2015DN01161A (fr)
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
TN2012000555A1 (en) Antibodies to human gdf8
EP3354640A3 (fr) Facteurs d'inhibition de la migration des macrophages (mif) et leurs utilisations
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
MX2013003076A (es) Terapeuticos contra cancer de mama.
EP3520793A3 (fr) Substances et compositions à utiliser dans des procédés d'inhibition de l'amyotrophie
IN2014CN02887A (fr)
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
MX2012014904A (es) Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
WO2012135697A3 (fr) Nouveaux inhibiteurs de la rho-kinase et leurs procédés d'utilisation
MX360030B (es) Metodos para tratar el trastorno bipolar.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2015004389A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2013007603A (es) Antagonistas de hedgehog que tienen residuos que se unen al zinc.
IL229020A0 (en) Fatty acid amide hydrolase inhibitors for pain management